Lodi News-Sentinel

What older patients need to know about Paxlovid

- Judith Graham KAISER HEALTH NEWS

A new coronaviru­s variant is circulatin­g, the most transmissi­ble one yet. Hospitaliz­ations of infected patients are rising. And older adults represent nearly 90% of U.S. deaths from COVID19 in recent months, the largest portion since the start of the pandemic.

What does that mean for people 65 and older catching COVID for the first time or those experienci­ng a repeat infection?

The message from infectious disease experts and geriatrici­ans is clear: Seek treatment with antiviral therapy, which remains effective against new COVID variants.

The therapy of first choice, experts said, is Paxlovid, an antiviral treatment for people with mild to moderate COVID at high risk of becoming seriously ill from the virus. All adults 65 and up fall in that category. If people can’t tolerate the medication — potential complicati­ons with other drugs need to be carefully evaluated by a medical provider — two alternativ­es are available.

“There’s lots of evidence that Paxlovid can reduce the risk of catastroph­ic events that can follow infection with COVID in older individual­s,” said Dr. Harlan Krumholz, a professor of medicine at Yale University.

Meanwhile, develop a plan for what you’ll do if you get COVID. Where will you seek care? What if you can’t get in quickly to see your doctor, a common problem? You need to act fast since Paxlovid must be started no later than five days after the onset of symptoms. Will you need to adjust your medication regimen to guard against potentiall­y dangerous drug interactio­ns?

“The time to be figuring all this out is before you get COVID,” said Dr. Allison Weinmann, an infectious-disease expert at Henry Ford Hospital in Detroit.

Being prepared proved essential when I caught COVID in mid-December and went to urgent care for a prescripti­on. Because I’m 67, with blood cancer and autoimmune illness, I’m at elevated risk of getting severely ill from the virus. But I take a blood thinner that can have life-threatenin­g interactio­ns with Paxlovid.

Fortunatel­y, the urgent care center could see my electronic medical record, and a physician’s note there said it was safe for me to stop the blood thinner and get the treatment. (I’d consulted with my oncologist in advance.) So, I walked away with a Paxlovid prescripti­on, and within a day my headaches and chills had disappeare­d.

Just before getting COVID, I’d read an important study of nearly 45,000 patients 50 and older treated for COVID between January and July 2022 at Mass General Brigham, a large Massachuse­tts health system. Twentyeigh­t percent of the patients were prescribed Paxlovid, which had received an emergency use authorizat­ion for mild to moderate COVID from the FDA in December 2021; 72% were not. All were outpatient­s.

Kaiser Health News is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at Kaiser Family Foundation, an endowed nonprofit organizati­on providing informatio­n on health issues to the nation.

Newspapers in English

Newspapers from United States